Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)
Substantial institutional variability exists in AGA testing for NSCLC, which was unexplained by patient or tumor characteristics. This objective evaluation of institution-based variability in testing may emphasize the importance of practice patterns on patient care and may therefore provide an avenue for change.
Authors
- Martin Sebastian (ORCID: https://orcid.org/0000-0002-0404-7741)
- Konrad Kokowski
- Friederike C. Althoff (ORCID: https://orcid.org/0000-0003-0702-5334)
- Henning Pelz
- Martina Jänicke
- Christian Grah (ORCID: https://orcid.org/0000-0003-3217-7495)
- Stefan Zacharias
- A. Fleitz (ORCID: https://orcid.org/0000-0002-8647-8480)
- Annika Groth
- Jörg Wiegand
- Paula Ludwig
- Marcel Reiser
- Wilfried E.E. Eberhardt
- Frank Griesinger
- Horst-Dieter Hummel
- Michael Thomas
- Arnd Nusch
Institutions
- Goethe University Frankfurt (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- München Klinik Bogenhausen (DE)
- Comprehensive Cancer Center Mainfranken (DE)
- Forschungsinstitut Havelhöhe (DE)
- Essen University Hospital (DE)
- Pius Hospital Oldenburg (DE)
- AIO Studien gGmbH (DE)
- Klinikum Dortmund (DE)
- German Center for Lung Research (DE)
- University Hospital Frankfurt (DE)
- Iomedico (Germany) (DE)
- Praxis für Hämatologie und Onkologie (DE)
- Frankfurt Cancer Institute (DE)
- Offenburg University of Applied Sciences (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.ejca.2026.116265
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00